Teva Pharmaceutical Industries Limited (TEVA) Cut to “Strong Sell” at BidaskClub

Teva Pharmaceutical Industries Limited (NYSE:TEVA) was downgraded by equities researchers at BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued on Thursday.

Other analysts have also issued reports about the company. Royal Bank Of Canada cut their price target on Teva Pharmaceutical Industries Limited from $21.00 to $15.00 and set an “underperform” rating on the stock in a report on Monday. Credit Suisse Group set a $39.00 price target on Teva Pharmaceutical Industries Limited and gave the company a “buy” rating in a report on Thursday, August 3rd. Maxim Group restated a “hold” rating and issued a $15.50 price target on shares of Teva Pharmaceutical Industries Limited in a report on Thursday, September 14th. Cantor Fitzgerald set a $31.00 price target on Teva Pharmaceutical Industries Limited and gave the company a “hold” rating in a report on Thursday, June 22nd. Finally, Vetr upgraded Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating and set a $34.17 price target on the stock in a report on Monday, July 24th. Five research analysts have rated the stock with a sell rating, nineteen have assigned a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Teva Pharmaceutical Industries Limited has a consensus rating of “Hold” and a consensus target price of $30.91.

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded up 0.23% during midday trading on Thursday, reaching $17.15. The company had a trading volume of 15,443,089 shares. The firm’s market cap is $17.42 billion. The company’s 50-day moving average is $18.13 and its 200-day moving average is $28.20. Teva Pharmaceutical Industries Limited has a 52-week low of $15.22 and a 52-week high of $51.51. Teva Pharmaceutical Industries Limited also was the recipient of unusually large options trading on Monday. Traders acquired 20,895 put options on the stock. This represents an increase of 103% compared to the typical daily volume of 10,273 put options.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by ($0.07). The business had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The business’s revenue was up 12.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.25 earnings per share. Equities research analysts expect that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was reported by Transcript Daily and is the property of of Transcript Daily. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://transcriptdaily.com/2017/09/22/teva-pharmaceutical-industries-limited-teva-cut-to-strong-sell-at-bidaskclub.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TEVA. Comerica Bank lifted its stake in Teva Pharmaceutical Industries Limited by 21.3% during the first quarter. Comerica Bank now owns 102,913 shares of the company’s stock worth $3,265,000 after purchasing an additional 18,092 shares during the last quarter. Stevens Capital Management LP bought a new stake in Teva Pharmaceutical Industries Limited during the first quarter worth $328,000. Conservest Capital Advisors Inc. bought a new stake in Teva Pharmaceutical Industries Limited during the first quarter worth $375,000. Airain ltd lifted its stake in Teva Pharmaceutical Industries Limited by 23.3% during the first quarter. Airain ltd now owns 656,894 shares of the company’s stock worth $21,080,000 after purchasing an additional 124,232 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. lifted its stake in Teva Pharmaceutical Industries Limited by 12.0% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 21,678 shares of the company’s stock worth $695,000 after purchasing an additional 2,322 shares during the last quarter. Hedge funds and other institutional investors own 56.76% of the company’s stock.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply